肺腺癌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Lung Adenocarcinoma Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月29日 | 出版商:

Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受肺癌（尤其是肺腺癌）發病率上升的推動，全球肺腺癌治療市場將於 2023 年擴大至 51 億美元，2024 年至 2032 年將以 10.5% 的複合年成長率成長。吸煙率、污染率和遺傳傾向的增加導致了這一上升趨勢。此外，標靶治療的創新可提高治療效果和患者預後，解決與腺癌相關的特定基因突變問題。這些進步提供了更個人化的治療選擇，並提高了存活率。隨著人們對這些療法的認知不斷增強，它們吸引了更多患者，進一步擴大了這一關鍵領域的市場規模。

肺腺癌治療產業根據治療類型、疾病階段、最終用途和地區而分散。

化療領域將在 2023 年達到 19 億美元，到 2032 年將以 10.2% 的複合年成長率成長，這得益於其廣泛用於治療晚期疾病。化療仍然是一種標準治療方法，通常單獨使用或與免疫療法或標靶治療等其他療法結合使用。即使在其他治療失敗的情況下，其在縮小腫瘤大小和控制疾病進展方面的有效性也鞏固了其領先地位。藥物配方的可及性增加和進步進一步促進了該細分市場的成長。

由於擁有先進的診斷和治療設施，醫院部門到 2024 年將獲得 32 億美元的收入，並在 2024 年至 2032 年實現 6.3% 的複合年成長率。醫院通常是實施化療、放療和標靶治療等複雜療法的主要中心。此外，專業醫療保健專業人員的存在和管理重症病例的能力也有助於該細分市場的主導地位。肺癌患者數量的增加和醫療基礎設施的改善進一步推動了該市場對醫院治療的需求。

由於完善的醫療基礎設施和肺癌病例的高盛行率，到 2032 年，北美肺腺癌治療市場將達到 57 億美元。該地區受益於先進的醫療技術、創新的治療方案以及對癌症研究的大力投資。此外，人們對早期診斷的認知不斷提高，醫療保健服務的普及也提高了治療效果。有利的報銷政策和日益老化的人口進一步推動市場成長，使北美成為全球肺腺癌治療產業的關鍵貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - 肺腺癌盛行率增加
  - 精準醫學和標靶治療的進展
  - 提高認知和早期發現計劃
- 產業陷阱與挑戰
  - 治療費用高
  - 不良反應和安全問題
成長潛力分析
監管環境
技術景觀
管道分析
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
手術
放射治療
化療
標靶治療
免疫療法
其他治療類型

第 6 章：市場估計與預測：按疾病階段，2021 - 2032 年

主要趨勢
第一階段和第二階段
第三階段
第四階段

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
專科診所
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson and Johnson Services, Inc.
Merck and Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

簡介目錄

Product Code: 11125

The Global Lung Adenocarcinoma Treatment Market expanded to USD 5.1 billion in 2023 and will grow at 10.5% CAGR from 2024 to 2032, driven by the rising incidence of lung cancer, particularly lung adenocarcinoma. Increasing rates of smoking, pollution, and genetic predispositions contribute to this upward trend. Also, innovations in targeted therapies enhance treatment effectiveness and patient outcomes, addressing specific genetic mutations associated with adenocarcinoma. These advancements provide more personalized treatment options and lead to improved survival rates. As awareness of these therapies grows, they attract more patients, further expanding the market size in this critical area.

The lung adenocarcinoma treatment industry is fragmented based on treatment type, stages of disease, end-use, and region.

The chemotherapy segment will reach USD 1.9 billion in 2023 and grow at a 10.2% CAGR through 2032, fueled by its widespread use in managing advanced stages of the disease. Chemotherapy remains a standard treatment, often utilized alone or in combination with other therapies like immunotherapy or targeted treatments. Its effectiveness in reducing tumor size and controlling disease progression, even in cases where other treatments fail, solidifies its leading position. Increased accessibility and advancements in drug formulations further bolster the growth of this segment in the market.

The hospitals segment will secure USD 3.2 billion by 2024 and achieve a 6.3% CAGR from 2024 to 2032, owing to the availability of advanced diagnostic and treatment facilities. Hospitals are often the primary centers for administering complex therapies such as chemotherapy, radiation, and targeted treatments. Additionally, the presence of specialized healthcare professionals and the ability to manage severe cases contribute to the segment's dominance. The growing number of lung cancer patients and improved healthcare infrastructure further drive the demand for hospital-based treatments in this market.

North America lung adenocarcinoma treatment market will capture USD 5.7 billion by 2032, attributed to a well-established healthcare infrastructure and high prevalence of lung cancer cases. The region benefits from advanced medical technologies, innovative treatment options, and strong investment in cancer research. Also, rising awareness about early diagnosis and improved access to healthcare services enhance treatment outcomes. Favorable reimbursement policies and an increasing aging population further propel market growth, making North America a key contributor to the global lung adenocarcinoma treatment industry.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of lung adenocarcinoma
  - 3.2.1.2 Advances in precision medicine and targeted therapies
  - 3.2.1.3 Rising awareness and early detection programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatments
  - 3.2.2.2 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Immunotherapy
5.7 Other treatment types

Chapter 6 Market Estimates and Forecast, By Stage of Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Stage I and II
6.3 Stage III
6.4 Stage IV

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa